TransMedics Group, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
TMDX$90.95-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash | $492,962 | $488,366 |
| Accounts receivable | 114,935 | 84,282 |
| Inventory | 58,373 | 48,881 |
| Prepaid expenses and other current assets | 26,186 | 16,254 |
| Total current assets | 692,456 | 637,783 |
| Property, plant and equipment, net | 376,490 | 327,656 |
| Finance lease right-of-use assets, net | 330,400 | — |
| Operating lease right-of-use assets, net | 4,342 | 5,155 |
| Deferred tax assets | 72,787 | 83,543 |
| Restricted cash | 18,438 | 500 |
| Goodwill | 18,015 | 11,549 |
| Acquired intangible assets, net | 2,815 | 1,948 |
| Other non-current assets | 2,194 | 239 |
| Total assets | $1,517,937 | $1,068,373 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $10,143 | $10,350 |
| Accrued expenses and other current liabilities | 82,757 | 62,740 |
| Current portion of long-term debt, net | 54,818 | 10,000 |
| Deferred revenue | 1,497 | 2,905 |
| Operating lease liabilities | 3,642 | 3,310 |
| Total current liabilities | 152,857 | 89,305 |
| Convertible senior notes, net | 454,994 | 452,804 |
| Long-term debt, net | — | 49,587 |
| Finance lease liability | 351,533 | — |
| Operating lease liabilities, net of current portion | 1,915 | 3,577 |
| Other long-term liabilities | 5,926 | — |
| Total liabilities | 967,225 | 595,273 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, no par value; 25,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, no par value; 150,000,000 shares authorized; 34,722,408 shares and 34,267,802 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 789,898 | 750,926 |
| Accumulated other comprehensive income (loss) | (306) | 124 |
| Accumulated deficit | (238,880) | (277,950) |
| Total stockholders’ equity | 550,712 | 473,100 |
| Total liabilities and stockholders’ equity | $1,517,937 | $1,068,373 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.